Dr. Rachel Mednick Thompson named inaugural chair holder
UCLA Health
The inaugural chair holder is Dr. Rachel Thompson, whose research focuses on the muscular pathology of cerebral palsy. Julie Kirst |
May 13, 2021
The David Geffen School of Medicine at UCLA has established the William and Patricia Oppenheim Presidential Chair in Pediatric Orthopaedics. The chair honors Dr. William Oppenheim, an internationally renowned expert in orthopaedics, and his wife, Patricia Schnegg.
In addition to the Oppenheims, numerous donors, including Shirley and Ralph Shapiro and their children, Peter and Alison, as well as colleagues, friends and former patients of William Oppenheim, contributed to fund the chair; their donations were bolstered by the University of California Presidential Match for Endowed Chairs program, for a total contribution of more than $1 million.
Share:
ISELIN, N.J., May 12, 2021 (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (NASDAQ:OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will host a Virtual Clinical Day for analysts and accredited institutional investors with live video webcast (details below) on Thursday, May 20, 2021 from 11:00 AM – 1:00 PM ET.
During the Virtual Clinical Day, Outlook Therapeutics will provide an overview of its lead program, ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), its ongoing Phase 3 study in wet AMD, NORSE TWO, and its plans for a potential commercial rollout.